{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:05:28Z","timestamp":1789239928879,"version":"build-2803163510"},"reference-count":29,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T00:00:00Z","timestamp":1738195200000},"content-version":"unspecified","delay-in-days":29,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Open Heart"],"accepted":{"date-parts":[[2025,1,15]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Mitral valve repair (MVr) is the gold standard treatment for degenerative mitral regurgitation, yet there is ongoing controversy regarding optimal anti-thrombotic therapy post-MVr. This scoping review aimed to summarise current evidence on the safety and efficacy of anti-thrombotic therapy after MVr, identify knowledge gaps and propose a future study design.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched MEDLINE, Embase, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, the WHO International Clinical Trials Registry Platform and bibliographies of included trials, guidelines and other reviews from inception to 17 September 2024. Randomised controlled trials (RCT) and cohort and case-control studies assessing any anti-thrombotic therapy with any outcomes after MVr were included. Using a predefined collection form, two authors independently extracted data on study characteristics and results were summarised narratively into themes based on the PICO elements.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 1296 screened references, we included 11 studies (10 cohort and one non-inferiority RCT). All studies compared vitamin K antagonist (VKA) to an anti-platelet, direct oral anti-coagulant or no anti-thrombotic therapy for median duration of 90 days. Thromboembolic and bleeding event incidences ranged from 0% to 14.3%\u2009and 0% to 9.1%, respectively. Seven studies reported no difference in thromboembolic events, and three reported reduced rates with VKA compared with control, while results for bleeding events varied widely. The RCT found edoxaban was non-inferior to warfarin for thromboembolic outcomes, but not for bleeding. Substantial methodological and clinical heterogeneity, high risk of bias and insufficient mitigation of confounders, such as concomitant atrial fibrillation, were prevalent across studies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Based on this scoping review, existing literature on anti-thrombotic therapy after MVr is inconclusive due to design limitations. We proposed a study design for a pragmatic RCT that addresses prior study limitations and that could provide definitive evidence to guide anti-thrombotic management in MVr patients.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/openhrt-2024-003158","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:00:17Z","timestamp":1738231217000},"page":"e003158","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Efficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-6007-2241","authenticated-orcid":false,"given":"Hazal Ece","family":"Babadagli","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Sciences, Vancouver General Hospital, Vancouver, British Columbia, Canada"},{"name":"The University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1939-7573","authenticated-orcid":false,"given":"Jian","family":"Ye","sequence":"additional","affiliation":[{"name":"Cardiac Surgery, St Paul's Hospital, Vancouver, British Columbia, Canada"},{"name":"Department of Surgery, The University of British Columbia - Vancouver Campus, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3153-1870","authenticated-orcid":false,"given":"Jenny","family":"Chen","sequence":"additional","affiliation":[{"name":"Pharmacy, Surrey Memorial Hospital, Surrey, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3967-1528","authenticated-orcid":false,"given":"Ricky","family":"Turgeon","sequence":"additional","affiliation":[{"name":"The University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada"},{"name":"Department of Pharmaceutical Sciences, St Paul's Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-2556","authenticated-orcid":false,"given":"Erica HZ","family":"Wang","sequence":"additional","affiliation":[{"name":"The University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, British Columbia, Canada"},{"name":"Department of Pharmaceutical Sciences, St Paul's Hospital, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,30]]},"reference":[{"key":"2025081709383461000_12.1.e003158.1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.91.4.1022"},{"key":"2025081709383461000_12.1.e003158.2","first-page":"II90","article-title":"Outcome of mitral valve repair or replacement: a comparison by propensity score analysis","volume":"108 Suppl 1","author":"Moss","year":"2003","journal-title":"Circulation"},{"key":"2025081709383461000_12.1.e003158.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.10.058"},{"key":"2025081709383461000_12.1.e003158.4","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/S0022-5223(20)31455-0","article-title":"Valve repair with Carpentier techniques. The second decade","volume":"99","author":"Deloche","year":"1990","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025081709383461000_12.1.e003158.5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx391"},{"key":"2025081709383461000_12.1.e003158.6","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab395"},{"key":"2025081709383461000_12.1.e003158.7","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2301"},{"key":"2025081709383461000_12.1.e003158.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2014.02.536"},{"key":"2025081709383461000_12.1.e003158.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2017.03.011"},{"key":"2025081709383461000_12.1.e003158.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2013.03.024"},{"key":"2025081709383461000_12.1.e003158.11","first-page":"576","article-title":"An audit of anticoagulation practice among UK cardiothoracic consultant surgeons following valve replacement\/repair","volume":"14","author":"Vaughan","year":"2005","journal-title":"J Heart Valve Dis"},{"key":"2025081709383461000_12.1.e003158.12","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2023.10.002","article-title":"Oral Anticoagulation Versus Antiplatelet Treatment After Mitral Valve Repair: A Systematic Review and Meta-Analysis","volume":"210","author":"Tom\u0161i\u010d","year":"2024","journal-title":"Am J Cardiol"},{"key":"2025081709383461000_12.1.e003158.13","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2025081709383461000_12.1.e003158.14","unstructured":"Covidence systematic review software, veritas health innovation, Melbourne, Australia. n.d. Available: www.covidence.org"},{"key":"2025081709383461000_12.1.e003158.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025081709383461000_12.1.e003158.16","doi-asserted-by":"crossref","first-page":"2887","DOI":"10.1111\/jocs.14902","article-title":"Anticoagulation following mitral valve repair","volume":"35","author":"Watt","year":"2020","journal-title":"J Card Surg"},{"key":"2025081709383461000_12.1.e003158.17","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jtcvs.2015.12.036","article-title":"Antiplatelet versus oral anticoagulant therapy as antithrombotic prophylaxis after mitral valve repair","volume":"151","author":"Paparella","year":"2016","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2025081709383461000_12.1.e003158.18","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-018-1724-0"},{"key":"2025081709383461000_12.1.e003158.19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijcard.2007.03.115","article-title":"Thromboembolic events early after mitral valve repair: incidence and predictive factors","volume":"126","author":"Meurin","year":"2008","journal-title":"Int J Cardiol"},{"key":"2025081709383461000_12.1.e003158.20","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s11239-020-02046-2","article-title":"Rivaroxaban in patients undergoing surgical mitral valve repair","volume":"49","author":"Noohi","year":"2020","journal-title":"J Thromb Thrombolysis"},{"key":"2025081709383461000_12.1.e003158.21","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.athoracsur.2022.09.038","article-title":"Risk of Stroke and Major Bleeding With Vitamin K Antagonist Use After Mitral Valve Repair","volume":"115","author":"Brown","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"2025081709383461000_12.1.e003158.22","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.athoracsur.2022.07.045","article-title":"Apixaban for Anticoagulation After Robotic Mitral Valve Repair","volume":"115","author":"Mazur","year":"2023","journal-title":"Ann Thorac Surg"},{"key":"2025081709383461000_12.1.e003158.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2021.01.127"},{"key":"2025081709383461000_12.1.e003158.24","doi-asserted-by":"publisher","DOI":"10.1093\/ejcts\/ezs626"},{"key":"2025081709383461000_12.1.e003158.25","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2015-308272"},{"key":"2025081709383461000_12.1.e003158.26","article-title":"Long-Term Effects of Postoperative Atrial Fibrillation following Mitral Valve Surgery","volume":"10","author":"Alghosoon","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"2025081709383461000_12.1.e003158.27","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2020.09.001"},{"key":"2025081709383461000_12.1.e003158.28","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.121218"},{"key":"2025081709383461000_12.1.e003158.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2005.06.015"}],"container-title":["Open Heart"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/openhrt-2024-003158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,17]],"date-time":"2025-08-17T16:38:44Z","timestamp":1755448724000},"score":1,"resource":{"primary":{"URL":"https:\/\/openheart.bmj.com\/lookup\/doi\/10.1136\/openhrt-2024-003158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,30]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/openhrt-2024-003158"],"URL":"https:\/\/doi.org\/10.1136\/openhrt-2024-003158","relation":{},"ISSN":["2053-3624"],"issn-type":[{"value":"2053-3624","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}